Investor Presentaiton
Appendix 4: Maxigesic dose forms extend the market
Revenue
MaxigesicⓇ family growth
Maxigesic® IV
Maxigesic® TABLETS
MaxigesicⓇ
DRY STICK SACHET
MaxigesicⓇ
COLD & FLU
MaxigesicⓇ RAPID
MaxigesicⓇ HOT DRINK SACHET
MaxigesicⓇ ORAL LIQUID
maxigesIC
Junior
Pomsel 180mg/5ml
Ibuprofen 4 mg/5 ml.
Ordi Suspersion
For children 2-12 years
OCUBLE
ACTION
RELIER
PAIN & FEVER
Strawberry flavour
Alohathenger to himpin ding yang
200 m
maxiqesiCNV
PHARMACIST ONLY MEDICINE
maxigesic
20 Cated
•
Estimated total analgesic market size
$6.2 billion, oral dose forms US5.4
billion and injectable forms US724
million**
Maxigesic tablets are patent protected
out to 2025-2028, beyond which the
brand name is expected to cement
Maxigesic's OTC position in the market
Time
AFT is now leveraging the brand goodwill into Maxigesic
variants, including:
-
Maxigesic PE (2034 patent)
-
Maxigesic Hot Drink Sachet (2025, 2028 patent)
-
Maxigesic Dry Stick Sachet (2036 patent)
Maxigesic IV (2034 [AU] 2031, 2035, 2037 [Global] patents)
―
- Maxigesic Oral Liquid (2025, 2028 patents)
Maxigesic Cold & Flu (2025, 2028 patents)
Maxigesic Rapid (2039 patents)
AFT pharmaceuticals *Maxigesic IV is a prescription product for hospital use *Management estimates
Page 24View entire presentation